Articles
| Open Access |
Vol. 3 No. 01 (2023): Volume03 Issue01
| DOI:
https://doi.org/10.37547/medical-fmspj-03-01-01
THE ROLE OF P53 AND BCL-2 GENE EXPRESSION IN BREAST CANCER THERAPY
Kadirova Dilbar Abdullaevna , Doctor Of Biological Sciences Professor, Institute Of Biophysics And Biochemistry At The National University Of The Republic Of Uzbekistan Khudoiberdieva Nilufar Valievna , Phd Doctorate, Tashkent. Emu University, National University Of The Republic Of Uzbekistan Palibaeva Zulfiya Khalmakhanovna , Phd In Biology, Medicine At European Medical University, Uzbekistan Suyunova Elmira Shavkidinovna , A Senior Lecturer Of Artificial Intelligence And Digital Technologies In Medicine At European Medical University, Uzbekistan Sultanbekova Iroda Azatbekovna , Tashkent Pediatric Medical Institute, UzbekistanAbstract
Breast cancer is one of the most common cancers in women. Statistical data of recent years indicate a steady, intensive increase in the incidence and mortality from breast cancer (BC) No specific genetic or epigenetic changes in tumor cells are known that are responsible for their aggressive behavior the process of metastasis, which is the main cause of death in cancer patients. An important role in the occurrence and development of breast cancer of the p53 gene, which protects the body from mutant cells, has been noted. Mutations in the p53 gene allow cells with damaged DNA to maintain mitotic activity. The incompleteness of apoptosis explains the different tumor sizes, non-invasive and slow tumor growth. The bcl-2 gene, in turn, suppresses cell apoptosis. The bcl-2 protein plays a key role in the regulation of apoptosis. Based on the foregoing, the analysis of the expression of the p53 gene, the bcl-2 proto-oncogene and the dependence of their expression on various factors during tumor formation are an important pathophysiological characteristic.
Keywords
Breast cancer, gene expression, p53
References
Lei, S., Zheng, R., Zhang, S., Wang, S., Chen, R., Sun, K., Wei, W. Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020 //Cancer Communications. – 2021. – Т. 41. – №. 11. – С. 1183-1194.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries //CA: a cancer journal for clinicians. – 2021. – Т. 71. – №. 3. – С. 209-249.
American Cancer Society. Breast cancer facts & figures 2019–2020 // Am. Cancer Soc. – 2019. – С.1 - 44.
Avezov N.Sh,., Kodyrova, D. A., Maksudova, A. N., Khudayberdiyeva, N. V., Boboev, K. T. "Mechanisms associated with the estrogen receptor and the TP53 gene of the rs1042522 locus in patients with breast cancer undergoing immunohistochemistry research."Advancing in research, practice and education 18 (2022): 61.
Avezov, N. Sh., Qodirova, D. A., Maksudova, A. N., Boboev, K. T. Assessment of the role of oncosupressor TR53 gene P47S polymorphism in breast cancer // Fundamental and applied scientific research: current issues, achievements and innovations. - 2020. - S. 152-155.
Avezov, N. Sh., Kodirova, D. A., Maksudova, A. N., Boboev, K. T. Determination of the contribution of the pro47ser polymorphism of the TP53 gene to the development of breast cancer // Concepts of sustainable development of science in modern conditions. - 2021. - S. 254-256.
Andersson J., Larsson L., Klaar S. et al. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF // Ann Oncol. - 2005. - Vol.16, №5. - p.743-748.
Ara S., Lee P.S., Hansen M.F., Saya H. Codon 72 polymorphism of the TP53 gene// Nucleic Acids Res. - 1990. - Vol.18, №16. - p.4961-4965.
Bergamaschi D., Gasco M., Hiller L. Р53 polymorphism influences response in cancer chemotherapy in modulation of p73-dependent apoptosis // Cancer Cell. -2003. - Vol.3, №4. - p.387-402.
Berns E.M., Foekens J.A., Vossen R. et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer // Cancer Res. - 2019. - Vol.60, №8. - p.2155-2162.
Berns E.M., Klijn J.G., Look M.P. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer // Clin Cancer Res. - 2011. - Vol.9, №4. - p.1253-1258.
Bertheau P., Espie M., Turpin E. et al. TP53 status and response to chemotherapy in breast cancer // Pathobiology. - 2008. - Vol.75, №2. - p.132-139.
Bielas J.H., Venkatesan R.N., Loeb L.A. LOH-proficient embryonic stem cells: a model of cancer progenitor cells? // Trends Genet. - 2017. - Vol.23, №4. - p.154-157.
Biros E., Kalina I., Kohut A., Stubna J., Salagovic J. Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer // Lung Cancer. - 2011. - Vol.31, №2-3. - p.157-162.
Bonafe M., Ceccarelli C., Farabegoli F. et al. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients // Clin Cancer Res. - 2003. - Vol.9, №13. - p.4860-4864.
Article Statistics
Downloads
Copyright License
Copyright (c) 2023 Kadirova Dilbar Abdullaevna , Khudoiberdieva Nilufar Valievna, Palibaeva Zulfiya Khalmakhanovna, Suyunova Elmira Shavkidinovna, Sultanbekova Iroda Azatbekovna
This work is licensed under a Creative Commons Attribution 4.0 International License.